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Lithium is a simple monovalent cation that represents one of the most important compounds used in psychiatry. It is widely used and remains the most effective treatment for mania and for the prevention of recurrent episodes in both mania and depression (Schildkraut 1973; Schou and Thomsen 1975; Wood and Goodwin 1987; Price et al. 1990; Odagaki et al. 1992; Price and Heninger 1994; Schou 1997; Gershon and Soares 1997; Soares and Gershon 1998) .
Despite extensive research, the molecular mechanism underlying its therapeutic action has not been fully elucidated, and no precise site of action has been identified yet, at least for therapeutic concentrations attained in the brain of patient. Nevertheless, a wide variety of biochemical effects have been reported, of which the most documented is the interaction of lithium with signal transduction pathways coupled to membrane receptors. Indeed, lithium has been shown to interact both with the phosphatidyl inositol turnover reducing brain inositol levels and with the adenylate cyclase activities, reducing receptor stimulated adenylate cyclase activity. These interactions of lithium are likely involved in the general profile of clinical activities of the ion (Wood and Goodwin 1987; Price and Heninger 1994; Manji et al. 1995; Belmaker et al. 1996; Attack 1996) . Focusing on the serotonergic system, whose activity is considered to be reduced in depression (Price et al. 1990; Odagaki et al. 1992; Siever et al. 1991; GrahameSmith 1992) , numerous reports have shown, in vitro as well as in vivo, that lithium has the capacity to induce an increase in the release of serotonin (5-hydroxytryptamine, 5-HT) at the synaptic level (Green and Grahame-Smith 1976; Treiser et al. 1981; Blier and de Montigny 1985; Hotta et al. 1986; Wood and Goodwin 1987; Blier et al. 1987; Friedman and Wang 1988; Wang and Friedman 1988; Hotta and Yamawaki 1988; Hide and Yamawaki 1989; Sharp et al. 1991; Price and Heninger 1994) and can also potentiate antidepressant treatments (de Montigny et al. 1983; Cowen et al. 1991; Baumann et al. 1996) . The biochemical mechanism responsible for these properties is not yet understood, although it has been suggested that 5-HT autoreceptors, and particularly 5-HT 1B, could be responsible for these effects (Blier and de Montigny 1985; Hotta et al. 1986; Friedman and Wang 1988; Wang and Friedman 1988; Hotta and Yamawaki 1988; Hide and Yamawaki 1989) .
However, neuronal 5-HT release can be modulated by different ways. A major one is interaction with its inactivating process, particularly the synaptosomal reuptake system, which is the target for classical antidepressant drugs as specific serotonin reuptake inhibitors (SSRIs) (Hyttel 1982; Owen et al. 1997) , and other ways consist in altering the activity of presynaptic 5-HT autoreceptors; that is, 5-HT 1A and 5-HT 1B receptor subtypes. 5-HT 1A autoreceptors are localized on the soma and dendrites of the 5-HT neurons and control their firing; whereas, 5-HT 1B autoreceptors are localized on neuron terminals, where they are especially dedicated to the auto control of the release of 5-HT (Hoyer et al. 1994) . With regard to the serotonin transporter or the 5-HT 1A receptor, results are rather controversial, because some studies have shown an interaction of lithium at these levels and others did not; whereas, few biochemical data were reported for 5-HT 1B receptor (Schildkraut 1973; Schou and Thomsen 1975; Treiser and Kellar 1980; Treiser et al. 1981; Wood and Goodwin 1987; Blier et al. 1987; Price et al. 1990; Odagaki et al. 1991; Odagaki et al. 1992; Plenge et al. 1992; Price and Heninger 1994; Okamoto et al. 1996; Schou 1997; Carli et al. 1997; Gershon and Soares 1997; Soares and Gershon 1998; Redrobe and Bourin 1999) . The aim of this study was to determine whether or not lithium could interact with the 5-HT system via this particular molecular target (5-HT 1B ), as was previously proposed (Blier and de Montigny 1985; Hotta et al. 1986; Friedman and Wang 1988; Wang and Friedman 1988; Hotta and Yamawaki 1988; Hide and Yamawaki 1989; Redrobe and Bourin 1999) . The potential alteration of 5-HT 1B terminal autoreceptor by lithium could induce an increase of the availability of 5-HT in the synaptic cleft presumably leading, as in the case of SSRI, to an antidepressant-like effect. Thus, 5-HT 1B could represent a primary target for lithium that could result in the necessary biochemical changes for lithium's therapeutic activity in the treatment of mood disorders. 
MATERIALS AND METHODS

Materials
Membrane Preparation
Receptor Bindings. Rat and guinea pig brain cortices were dissected on ice and homogenized for 30 seconds with an Ultra-Turrax apparatus in 5 volumes (v/w) of a 50 mM Tris-HCl buffer pH 7.4 containing 2 mM ethylenediaminetetra-acetic acid (EDTA), 0.1 mM phenyl methyl sulfonyl fluoride, and 5 IU/L aprotinin. The homogenate was then diluted in 30 volumes (v/w) of the same medium, incubated for 10 minutes at 37 Њ C to remove endogenous ligands, and centrifuged (17,500 ϫ g at 4 Њ C for 5 min). The resulting pellet was resuspended in 5 volumes of the same buffer, incubated for 10 minutes at 37 Њ C, and centrifuged as described above. The homogenate was washed two additional times, and the pellet was resuspended in the appropriate incubation buffer.
NIH 3T3 or CHO cells (10 6 /dish) were cultured for 48 hours in a Dulbecco's modified Eagle's medium supplemented with 10% calf serum, 0.3 mg/ml geniticin, 10 IU/L penicillin, and 10 g/ml streptomycin. Cells were then collected and extensively washed in a 50 mM TrisHCl buffer, pH 7.4, before homogenization. Membranes were then prepared as described above.
Uptake and Release. Rat brain synaptosomes (total brain minus cerebellum) were prepared according to the method of Cotman and Matthews (1971) .
Human Blood Platelets. Blood samples, collected in tubes containing a 3.8% sodium citrate solution, were centrifuged (180 ϫ g /10 min/4 Њ C). The supernatant was kept at 4 Њ C, and the pellet was centrifuged once again (180 ϫ g /10 min/4 Њ C). The two supernatants were pooled and centrifuged (1,500 ϫ g /10 min/4 Њ C). The supernatant was centrifuged once again (3500 ϫ g / 20 min/4 Њ C). The pellet was resuspended in a 50 mm Tris-HCl buffer pH 7.4 at 25 Њ C containing 2 mM dithiothreitol and 1 mM EDTA, homogenized for 5 s with a polytron and centrifuged (18,000 ϫ g /20 min/ 4 Њ C).
[ 35 S]GTP ␥ S Binding. CHO cells stably expressing h5-HT 1B receptor protein were harvested in a cold phosphate buffer pH 7.4 containing 0.1 mM EDTA and centrifuged (20 min/48,000 ϫ g /4 Њ C). The pellet was then homogenized with a polytron in a 20 mm Hepes buffer pH 7.4 containing 10 mM EDTA and centrifuged (48,000 ϫ g /4 Њ C /10 min). The resulting pellet was washed twice in a 20 mM Hepes buffer pH 7.4 containing 0.1 mM EDTA, homogenized, and centrifuged (48,000 ϫ g /10 min/4 Њ C) (Thomas et al. 1995) . The pellet was then stored at Ϫ 80 Њ C in fractions of 0.8 to 1 mg protein/ml until use.
Adenylate Cyclase Experiments. h5-HT 1B CHO transfected cells were collected, extensively washed in a 50 mM Tris-HCl buffer pH 7.4, and centrifugated.
Protein Measurement. Protein equivalents were determined according to the method of Lowry et al. (1951) . Bovine serum albumin was used as standard.
Dose-Response Curve on 5-HT 1B Receptors
Binding of [ . At the end of the incubation period, the tubes were cooled on ice and filtered under vacuum on Whatman GF/B glass fiber filters. Each filter was washed twice with 5 ml of ice-cold incubation buffer and dried. The radioactivity retained on the filter was then measured by liquid scintillation counting. 5-HT 1B specific binding was determined by the difference between total (5-HT 1nonA ) and 5-HT 1E/1F bindings (Palacios et al. 1993) . 
Saturation Experiments
Pharmacological Specificity
Each binding was measured in the presence/absence of 1 mM LiCl. Binding of [ Binding to cholinergic muscarinic receptors was determined with [ 3 H]QNB (3 nM) on rat brain membranes for 30 min at 25ЊC in a buffer composed of 50 mM TrisHCl pH 7.4, 120 mM NaCl and 50 mM KCl. Nonspecific binding was measured in the presence of 10 M atropine.
Binding to ␤-adrenergic receptors was performed on rat brain membranes with [ Uptake of 5-HT was conducted on rat brain synaptosomes (500 g/ml). They were incubated for 15 min at 37ЊC in an oxygenated Krebs-Henseleit buffer pH 7.4 (125 mM NaCl, 3 mM KCl, 1 mM NaH 2 PO 4 , 1.2 mM CaCl 2 , 1.2 mM MgSO 4 , 22 mM NaHCO 3 , 0.01% ascorbic acid and 10 mm glucose) in the presence of 20 nM [ 3 H]5-HT. Passive uptake was measured at 4ЊC. Reactions were stopped by the addition of 2 ml of ice-cold incubation buffer (4ЊC) and rapid filtration through Whatman GF/B glass fiber filters.
Specificity of Lithium versus Other Salts
The effect of lithium on h5HT 1B receptors (CHO cell membranes) was compared to effects of other monovalent (Cs 
Adenylate Cyclase Activity
The pellet of h5-HT 1B CHO transfected cells was resuspended (100 gml
Ϫ1
) and homogenized with a Potter apparatus in a 50 mM Tris-HCl buffer pH 7.4 (25ЊC). Dose-response curves of lithium were performed on the maximal inhibitory effect of 5-HT (1M) on the Forskolin-stimulated adenylate cyclase activity in a final volume of 200 l. The incubation buffer was composed in a 50 mM Tris-HCl buffer pH 7.4 (25ЊC) containing 4 mM MgCl 2 , 0.2 mM ATP, 20 M GTP, 20 mM phosphocreatine, 0.2 mg/ml creatin-kinase, 30 M Forskolin, 2 mM 3-isobutyl-1-methylxanthine, 1 Ci of [␣ 32 P]ATP and 30,000 cpm of [ 3 H]cAMP to quantify the recovery, the reaction being initiated by the addition of 50 l of the membrane preparation. After an incubation period of 10 min at 30ЊC, the reaction was stopped by the addition of 200 l of a 50 mM Tris-HCl buffer pH 7.4 (4ЊC) containing 1% (w/v) sodium dodecyl sulfate, 5 mM cAMP and 5 mM ATP. The amount of [␣ 32 P]cAMP formed was separated by sequential chromatography on Dowex and alumina columns.
Synaptosomal Release of [ 3 H]5-HT
Rat brain synaptosomes (500 g/ml) were loaded with 30 nM [ 3 H]5-HT for 15 min at 37ЊC in an oxygenated Krebs-Henseleit buffer pH 7.4. The homogenate was washed twice by centrifugation (17,500 ϫ g/5 min/4ЊC, and the resulting pellet was resuspended in the same buffer. 200 g aliquots of the synaptosomal preparation were then dispatched in a 96-well filtration plate (glassfiber filter type B). CP 93,129 (0.1 nM to 1 M), LiCl (1 mM), or both, were then added and incubated for 5 min with the loaded synaptosomes. At the end of the incubation period, a 5-min K ϩ stimulation (15 mM) was applied. The 96-well filtration plate was rapidly filtered, and the 96 filtrates were recovered and counted by liquid scintillation.
Adenylate Cyclase Experiments on Human Blood Platelets
Platelet preparation (300,000 ml Ϫ1 ) was resuspended and tested under the experimental conditions previously described for cyclase asays. Dose-response curves of L694,247 (0.1 nM to 10 M) were performed in the absence or presence of LiCl (0.01, 0.1, and 1 mM).
Behavior
The social interaction test was performed in mice (Francès 1988; Francès et al. 1990 ). Briefly, mice were either housed in groups of five animals or isolated for 1 week. They were tested in pairs (one grouped and one isolated), tested mice being placed under a transparent beaker inverted onto a rough surface glass plate. The number of escape attempts was counted for 2 min and defined as one of the following: (1) the forepaws were placed against the beaker wall; (2) the mouse sniffed at the rim of the beaker; or (3) the mouse scratched the glass floor. LiCl (2 mg/kg) or sodium chloride (for control) were injected ICV (intracerebroventricular) 45 min before the test, and RU 24,969 (4 mg/kg) was injected IP (intraperitoneally) 30 min before the test.
Mathematical Analysis
Binding experiments were analyzed under Prism 2.01 (GraphPad software, San Diego, CA), and statistical analyses were conducted using Student's t-test or twoway analysis of variance (ANOVA) performed under StatMate (GraphPad software, San Diego, CA).
RESULTS
Molecular Interaction of Lithium with 5-HT 1B Receptors
Effect of Lithium on 5-HT 1B Receptors. A series of experiments was carried out to establish displacement curves of lithium on 5-HT 1B binding at the full occupancy of receptor sites. This binding was measured in rat brain membranes using [ Figure 1A ). This result was confirmed by using cells transfected with either the gene coding for the r5-HT 1B receptor or the gene coding for the h5-HT 1B receptors. These receptors are the species homologs of 5-HT 1B receptors (rat and human, respectively) and are characterized by differences not only in their aminoacid sequences but also in their pharmaco- logical profiles (Hoyer et al. 1994) . 5-HT 1B binding to either cells was affected by lithium with similar IC 50 (0.64 Ϯ 0.01 and 0.32 Ϯ 0.06 mM for r and h5-HT 1B, respectively) ( Figure 1B,C) .
Effect of Lithium on Various Receptor Bindings.
To assess the pharmacological specificity of this interaction, the effect of lithium was further tested on bindings to various other receptors including the other 5-HT autoreceptors (r5-HT 1B labeled with [ ]5-HT uptake in rat brain synaptosomes. None of these bindings was significantly affected by lithium, at 1 mM, a concentration that inhibited 60 Ϯ 5% of the control 5-HT 1B binding. At the same concentration, lithium was neither able to alter the neuronal 5-HT uptake (Figure 2) . ,4247 (20-500 pM) to h5-HT 1B receptors. Guinea pig brain membranes (500 g) were incubated for 30 min at 25ЊC. Nonspecific binding was determined in the presence of 10 M 5-HT. Experiments were carried out with (᭺-᭺) or without (᭹-᭹) 1 mM LiCl. Each point is the mean Ϯ SEM of triplicate determinations of a typical experiment. This experiment was repeated three times. Right panels show the saturation curves and left panels represent their corresponding Scatchard plots (Scatchard 1949) . concentration, prevented 60 Ϯ 5% of this binding (Figure 3) .
Effect of Other Cations on 5-HT
Analysis of the Inhibitory Effect of Lithium on 5-HT 1B
Receptors. The molecular mechanism underlying this interaction of lithium has been studied performing saturation curves of [ 3 H]5-HT on the two species homologous of 5-HT 1B receptor (r5-HT 1B and h5-HT 1B ). In brain, specific radioligands were used; whereas, in transfected cells, [ (Figures 4 and 5) . Parallel Scatchard plots of the saturation curves clearly indicated that the interaction of lithium did not correspond to a competitive inhibition but rather suggested that it likely corresponded to a noncompetitive phenomenon (Figures 4 and 5) .
Functional Interaction of Lithium with 5-HT 1B Receptors
Effect of lithium on [ 35 S]GTP␥S Binding. The question of the functional relevance of the observed molecular interaction was also addressed using different experimental paradigms. A first series of assays consisted of testing the ability of lithium to interact with the second messenger system related to 5-HT 1B receptors; that is, the adenylate cyclase. Indeed, 5-HT 1B receptors can couple to Gi proteins and their activation can lead to an inhibition of the adenylate cyclase activity (Hoyer et al. 1994 ; Thomas et al. 1995 ). (Thomas et al. 1995; Pauwels et al. 1997) . Indeed, the binding of [ Moreover, this result was confirmed in assays directly measuring the enzyme (adenylate cyclase) activity. The effect of lithium was determined on the inhibitory activity of 5-HT (1 M) on the cAMP formation primarily induced by Forskolin in h5-HT 1B CHO transfected cells where lithium was also able to inhibit this activity with a similar EC 50 (0.49 Ϯ 0.02 mM), (Figure 6B ). Release experiments were carried out using rat cortical synaptosomes previously loaded with [ 3 H]5-HT. Under these conditions, a 5-HT 1B agonist (CP93,129) promoted, in a dose-dependent manner, a 44 Ϯ 5% inhibition of the K ϩ -evoked release of the tritiated amine with an IC 50 value of 25.7 Ϯ 0.7 nM. LiCl, at 1 mM, partially reversed the latter inhibitory effect, because the IC 50 of CP93,129 was shifted to 631 Ϯ 53 nM (Figure 7) .
Behavioral Studies. To test the effect of lithium in an in vivo situation, behavioral studies were performed using a test previously shown to be 5-HT 1B -specific: the social interaction test in mice (Francès 1988; Francès et al. 1990 ). Mice were isolated for 1 week to induce a behavioral change characterized by a deficit in the exploratory activity of the animals when placed in the presence of a congener: 62% reduction of the number of escape attempts (19.2 Ϯ 0.78 escape attempts for grouped mice vs. 7.4 Ϯ 1.3 for isolated mice). The administration of a 5-HT 1B agonist (RU24,969; 4 mg/kg) to isolated mice totally abolished this deficit (17.3 Ϯ 1.7 escape attempts) and the injection of lithium (2 mg/kg) was able to prevent the latter 5-HT 1B mediated effect (5.9 Ϯ 1.2 escape attempts); whereas, it had no significant effect on its own (5.8 Ϯ 1.1 escape attempts) (Figure 8) .
Interaction of Lithium with 5-HT 1B Receptors in
Humans: Effect on 5-HT 1B Cyclase-Dependent Activity in Human Blood Platelet.
Further investigations were conducted to examine whether or not these results could also apply to the clinical field. Studies were carried out on human blood platelets, which contain 5-HT 1B receptors (unpublished results). In this preparation, the activity of 5-HT 1B receptors was determined by measuring adenylate cyclase activity in the presence/absence of lithium.
Under these conditions, Forskolin (10 M) promoted a 10-fold simulation of the basal adenylyl cyclase activity (measured by the cAMP formation) and L694,247, a h5-HT 1B agonist, dose dependently reduced this activation with an EC 50 value of 32.5 nM and a maximal effect of 15%. LiCl, at various concentrations ranging from 10 M to 10 mM, was able to reverse this effect dose dependently and, at 1mM, LiCl totally abolished the L694,247 activity (Figure 9 ).
DISCUSSION
The experimental work presented here demonstrates that lithium has the capacity to interact specifically with 5-HT 1B receptors at concentrations ranging from 0.5 to 1 mM. This interaction seems to be ion and receptor specific. It is noteworthy that the human homolog of the 5-HT 1B receptors is also sensitive to lithium within the same concentration range. In terms of biochemical Figure 8 . Effect of lithium on the social interaction test in mice. The social interaction test was performed in mice (Francès 1988) , measuring the number of escape attempts of isolated treated mice. Results are expressed as the mean Ϯ SEM of escape attempts per mouse from three independent experiments. In each series, five mice were tested in each group, and each mouse was tested only once. Statistical analysis were conducted using Student's t-test where *** corresponds to p Ͻ .001. Isolated mice presented a behavioral deficit revealed by the reduction of the number of escape attempts (19.2 Ϯ 0.78 escape attempts for grouped mice vs. 7.4 Ϯ 1.3 for isolated mice). This deficit was reversed by RU24,969 (17.3 Ϯ 1.7 escape attempts), and LiCl suppressed the RU24, 969's effect (5.9 Ϯ 1.2 escape attempts); whereas, it had no significant effect on its own (5.8 Ϯ 1.1 escape attempts). mechanism, it corresponds to a noncompetitive inhibition (parallel Scatchard plots), suggesting that lithium probably acts on a site distinct from that binding 5-HT, although located on the 5-HT 1B receptor protein. The interaction of lithium with 5-HT 1B receptors was revealed at every level of the functioning of the receptor. This was shown at the molecular level (binding studies) and at the functional level, in studies dealing either with the effector system coupled to 5-HT 1B receptors ([ These results strengthen the hypothesis that the serotonergic terminal autoreceptor (5-HT 1B ) actually constitutes a direct molecular target for lithium. This conclusion is also supported by the findings of Redrobe and Bourin (Redrobe and Bourin 1999) , who demonstrated that, in the mouse forced swimming test, lithium promotes an antidepressant-like effect, in reducing the immobility time of the animals, presumably by acting on 5-HT 1B receptors.
From a clinical point of view, it is of interest to underline that the action of lithium on 5-HT 1B receptors is also observed in human materials, not only in vitro on h5-HT 1B transfected cells but also ex vivo, in human blood platelets. Thus, these experiments strongly suggest that the interaction of lithium with 5-HT 1B receptors, observed in animal material as well as in cells transfected with animal or human genes, is likely to be extended to human tissue. Moreover, this effect occurs at concentrations of lithium (0.1-1 mM), which correlates well with the relevant therapeutic concentrations attained in the brain of patients (Schildkraut 1973; Schou and Thomsen 1975; Price et al. 1990; Odagaki et al. 1992; Schou 1997; Gershon and Soares 1997; Soares and Gershon 1998) .
The fact that the therapeutic effect of lithium is generally observed after 2-3 of weeks treatment; whereas, the biochemical effect of the ion on 5-HT 1B receptor desensitization is rapid, does not preclude the involvement of 5-HT 1B receptors as primary targets for the relevant therapeutic effect of lithium. Indeed, the increase of serotonergic activity, rapidly induced by lithium, presumably leads to a cascade of mechanisms of regulation responsible for the final therapeutic activity of lithium occurring after a delay. Indeed, a very similar situation is observed with SSRI.
When the clinical effect of a drug is observed after a chronic treatment, it can be hypothesized that this effect is the result of a new homeostasis in the brain induced by its primarily direct action, which leads either directly or indirectly to the final observed effect. Because very few studies have dealt with the acute effect of lithium, it was of interest to define its direct molecular action (primarily targets). Thus, the interaction of lithium with 5-HT 1B receptors, shown in this series of experiments, may explain some of its clinical properties. In particular, reported beneficial effects observed in mood disorders may, at least partly, originate from the ability of lithium to facilitate the serotonergic transmission known to be altered in these pathologies (Price et al. 1990; Siever et al. 1991; Grahame-Smith 1992; Odagaki et al. 1992) . Indeed, the desensitization of 5-HT 1B autoreceptors, induced by lithium, results in a decrease of the efficacy of the negative retrocontrol of the 5-HT release at neurone terminals, leading to an increase of the release of 5-HT, and thus, to an enhancement of the availability of 5-HT in the synaptic cleft. This mechanism is in agreement with previous observations showing that lithium has the capacity to enhance 5-HT efflux at nerve terminals (Green and Grahame-Smith 1976; Treiser et al. 1981; Blier and de Montigny 1985; Hotta et al. 1986; Blier et al. 1987; Friedman and Wang 1988; Wang and Friedman 1988; Hotta and Yamawaki 1988; Hide and Yamawaki 1989; Sharp et al. 1991 ) and could also account for the increased benefit in the therapeutic action of antidepressant drugs when associated with lithium (de Montigny et al. 1983; Cowen et al. 1991; Baumann et al. 1996) .Antidepressants, particularly SSRIs, promote enhancement of the availability of 5-HT at the synaptic level by blocking the reuptake of the amine (Hyttel 1982; Owen et al. 1997) , and lithium seems to have a similar effect by reducing the 5-HT 1B auto receptor activity. Thus, a kind of synergism between lithium and antidepressants may significantly enhance the serotonergic activity in treated patients.
In conclusion, 5-HT 1B receptors constitute a newly identified molecular target for lithium. In this regard, this result opens new insights in the field of psychiatric research. First, it should substantially enhance our understanding of the biology of mania, manic depressive illness, aggression, and suicidal behavior, which are all markedly affected by lithium; and, second, it should facilitate development of alternative treatment or elaboration of novel promising therapeutic agents, because lithium is a very valuable drug, but one with substantial side-effects and a very low therapeutic safety index (Schildkraut 1973; Schou and Thomsen 1975; Wood and Goodwin 1987; Price et al. 1990; Odagaki et al. 1992; Price and Heninger 1994; Schou 1997; Gershon and Soares 1997; Soares and Gershon 1998) .
